Japan's Ministry Holds Strategy Meeting On Hepatitis Treatment
This article was originally published in PharmAsia News
To promote the development of new drugs and treatment for viral hepatitis B and hepatitis C, the Ministry of Health, Labor and Welfare established a Hepatitis Treatment Strategy Council and will hold the first meeting May 27. The meeting will discuss such topics as reducing the side effects of current treatments, treatments for relapsing patients and the development of the next generation of antiviral and cirrhosis drugs. The meeting will also discuss measures such as increased budget funding and more basic research to encourage development of new therapeutic drugs. (Click here for more - Japanese language
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.